-
Two-stage approach for risk estimation of fetal trisomy 21 and other aneuploidies using computational intelligence systems.
Neocleous AC, Syngelaki A, Nicolaides KH, Schizas CN.
Ultrasound Obstet Gynecol 2018;51:503-508. pdf -
Intelligent Non-invasive Diagnosis of Aneuploidy: Raw Values and Highly Imbalanced Dataset.
Neocleous A, Nicolaides K, Schizas C.
IEEE J Biomed Health Inform 2017;21:1271-1279. pdf -
First Trimester Noninvasive Prenatal Diagnosis: A Computational Intelligence Approach.
Neocleous AC, Nicolaides KH, Schizas CN.
IEEE J Biomed Health Inform 2016;20:1427-38. pdf -
Screening at 11-13+6 weeks' gestation.
Sonek JD, Nicolaides KH, Janku P.
Ceska Gynekol 2012;77:92-104. -
Yolk sac diameter in early pregnancy in maternal diabetes mellitus.
Papaioannou GI, Syngelaki A, Maiz N, Ross JA, Nicolaides KH.
Gynecol Obstet Invest 2012;73:16-20. -
Sonographic markers of aneuploidies at 6-10 weeks of gestation.
Papaioannou GK, Syngelaki A, Maiz N, Ross JA, Nicolaides KH.
Early Hum Dev 2011;87:453-6. -
Ultrasonographic prediction of early miscarriage.
Papaioannou GI, Syngelaki A, Maiz N, Ross JA, Nicolaides KH.
Hum Reprod 2011;26:1685-92. -
Prediction of outcome in dichorionic twin pregnancies at 6-10 weeks' gestation.
Papaioannou GI, Syngelaki A, Maiz N, Ross JA, Nicolaides KH.
Am J Obstet Gynecol 2011;205:3481-5. -
Screening for fetal aneuploidies at 11 to 13 weeks.
Nicolaides KH.
Prenat Diagn 2011;31:7-15. -
A model for a new pyramid of prenatal care based on the 11 to 13 weeks' assessment.
Nicolaides KH.
Prenat Diagn 2011;31:3-6. -
Additional first-trimester ultrasound markers.
Sonek J, Nicolaides K.
Clin Lab Med 2010;30:573-92. -
Normal ranges of embryonic length, embryonic heart rate, gestational sac diameter and yolk sac diameter at 6-10 weeks.
Papaioannou GI, Syngelaki A, Poon LC, Ross JA, Nicolaides KH.
Fetal Diagn Ther 2010;28:207-19. -
Fetal nasal bone in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation.
Kagan KO, Cicero S, Staboulidou I, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2009;33:259-64. -
First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
Sonek J, Cicero S, Nicolaides K.
Am J Obstet Gynecol 2007;196:19. -
Nasal bone in first-trimester screening for trisomy 21.
Cicero S, Avgidou K, Rembouskos G, Kagan KO, Nicolaides KH.
Am J Obstet Gynecol 2006;195:109-14. -
Assessment of the gap between the fetal nasal bones at 11 to 13 + 6 weeks of gestation by three-dimensional ultrasound.
Peralta CF, Falcon O, Wegrzyn P, Faro C, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;25:464-7. -
Gestational sac volume measured by three-dimensional ultrasound at 11 to 13 + 6 weeks of gestation: relation to chromosomal defects.
Falcon O, Wegrzyn P, Faro C, Peralta CF, Nicolaides KH.
Ultrasound Obstet Gynecol 2005;25:546-50. -
Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S, Spencer K, Avgidou K, Faiola S, Nicolaides KH.
Prenat Diagn 2005;25:977-83. -
Assessment of the fetal nasal bone at 11-14 weeks of gestation by three-dimensional ultrasound.
Rembouskos G, Cicero S, Longo D, Vandecruys H, Nicolaides KH.
Ultrasound Obstet Gynecol 2004;23:232-6. -
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
Nicolaides KH.
Am J Obstet Gynecol 2004;191:45-67.